Abstract
Introduction: The SEWA cell line, which is derived from a virus-induced murine osteosarcoma (OS) ascites, was established in the 1980s from a serially transplanted male-derived tumor that was first published in 1961. It has been applied in about 50 studies but was never genetically characterized in detail; this study fills that gap. Methods: The SEWA cell line was analyzed for its chromosomal constitution using molecular cytogenetic approaches. Array comparative genomic hybridization was performed to characterize copy number alterations. Results: SEWA has a near-diploid karyotype without Y-chromosome material. The complex karyotype includes neocentrics and simple and complex rearrangements. Amplification of MYC oncogene was detected in two homogeneously staining regions on two different derivative chromosomes. Conclusion: An in silico translation of the obtained results to the human genome indicated that SEWA is suitable as a model for advanced human OS.
Journal Section:
Brief Report
References
1.
Kim
HJ
, Chalmers
PN
, Morris
CD
. Pediatric osteogenic sarcoma
. Curr Opin Pediatr
. 2010
;22
(1
):61
–6
. 2.
Gill
J
, Gorlick
R
. Advancing therapy for osteosarcoma
. Nat Rev Clin Oncol
. 2021
;18
(10
):609
–24
. 3.
St. Jude care & treatment (stjude.org)
. Osteosarcoma treatment
. [cited 2024 Oct 1]. Available from: https://www.stjude.org/care-treatment/treatment/childhood-cancer/solid-tumors/osteosarcoma.html4.
Ozaki
T
, Schaefer
KL
, Wai
D
, Buerger
H
, Flege
S
, Lindner
N
, et al. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas
. Int J Cancer
. 2002
;102
(4
):355
–65
. 5.
Atiye
J
, Wolf
M
, Kaur
S
, Monni
O
, Böhling
T
, Kivioja
A
, et al. Gene amplifications in osteosarcoma-CGH microarray analysis
. Genes Chromosomes Cancer
. 2005
;42
(2
):158
–63
. 6.
Sjogren
HO
, Hellström
I
, Klein
G
. Transplantation of polyoma virus-induced tumors in mice
. Cancer Res
. 1961
;21
(1
):329
–37
.7.
Levan
G
, Mandahl
N
, Bregula
U
, Klein
G
, Levan
A
. Double minute chromosomes are not centromeric regions of the host chromosomes
. Hereditas
. 1976
;83
(1
):83
–90
. 8.
Levan
G
, Mandahl
N
, Bengtsson
BO
, Levan
A
. Experimental elimination and recovery of double minute chromosomes in malignant cell populations
. Hereditas
. 1977
;86
(1
):75
–90
. 9.
Jakobsson
AH
, Arnason
U
, Levan
A
, Martinsson
T
, Hanson
C
, Levan
G
. Novel cytogenetic expression of gene amplification in actinomycin D-resistant somatic cell hybrids: transfer of resistance by centric chromatin bodies
. Chromosoma
. 1987
;95
(6
):408
–18
. 10.
Schwab
M
, Ramsay
G
, Alitalo
K
, Varmus
HE
, Bishop
JM
, Martinsson
T
, et al. Amplification and enhanced expression of the c-myc oncogene in mouse SEWA tumour cells
. Nature
. 1985
;315
(6017
):345
–7
. 11.
Martinsson
T
, Ståhl
F
, Pollwein
P
, Wenzel
A
, Levan
A
, Schwab
M
, et al. Tumorigenicity of SEWA murine cells correlates with degree of c-myc amplification
. Oncogene
. 1988
;3
(4
):437
–41
.12.
Kubicova
E
, Trifonov
V
, Borovecki
F
, Liehr
T
, Rincic
M
, Kosyakova
N
, et al. First molecular cytogenetic characterization of murine malignant mesothelioma cell line AE17 and in silico translation to the human genome
. Curr Bioinform
. 2017
;12
(1
):11
–8
. 13.
14.
Azawi
S
, Balachandran
M
, Kramer
F
, Kankel
S
, Rincic
M
, Liehr
T
. Molecular cytogenetic characterization of the urethane-induced murine lung cell line LA-4 as a model for human squamous cell lung cancer
. Mol Clin Oncol
. 2022a
;16
(1
):9
. 15.
Azawi
S
, Kramer
F
, Liehr
T
, Rincic
M
. First cytogenomic characterization of murine cutaneous sarcoma cell line TSC2ang1
. Sci Technol Engineer J
. 2022b
;8
(1
):1
–16
.16.
DSMZ [Internet]
. SEWA
. [cited 2024 Oct 1]. Available from: https://www.dsmz.de/collection/catalogue/details/culture/ACC-52317.
Forus
A
, Weghuis
DO
, Smeets
D
, Fodstad
O
, Myklebost
O
, van Kessel
AG
. Comparative genomic hybridization analysis of human sarcomas: I. Occurrence of genomic imbalances and identification of a novel major amplicon at 1q21-q22 in soft tissue sarcomas
. Genes Chromosomes Cancer
. 1995
;14
(1
):8
–14
. 18.
Deeb
G
, Baer
MR
, Gaile
DP
, Sait
SN
, Barcos
M
, Wetzler
M
, et al. Genomic profiling of myeloid sarcoma by array comparative genomic hybridization
. Genes Chromosomes Cancer
. 2005
;44
(4
):373
–83
. 19.
Mihic-Probst
D
, Zhao
J
, Saremaslani
P
, Baer
A
, Oehlschlegel
C
, Paredes
B
, et al. CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma
. Anticancer Res
. 2004
;24
(1
):19
–26
.20.
Levan
A
, Levan
G
, Mandahl
N
. A new chromosome type replacing the double minutes in a mouse tumor
. Cytogenet Cell Genet
. 1978
;20
(1–6
):12
–23
. 21.
Cellosaurus [Internet]
. SEWA
. [cited 2024 Oct 1]. Available from: https://www.cellosaurus.org/CVCL_1N7922.
Martinsson
T
, Tenning
P
, Lundh
L
, Levan
G
. Methotrexate resistance and double minutes in a cell line from the SEWA mouse ascites tumor
. Hereditas
. 1982
;97
(1
):123
–37
. 23.
Creative Bioarray [Internet]
. SEWA
. [cited 2024 Oct 1]. Available from: https://www.creative-bioarray.com/SEWA-CSC-C1115-item-1573.htm24.
McCormack
A
, Fan
JL
, Duesberg
M
, Bloomfield
M
, Fiala
C
, Duesberg
P
. Individual karyotypes at the origins of cervical carcinomas
. Mol Cytogenet
. 2013
;6
(1
):44
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
